SlideShare uma empresa Scribd logo
1 de 39
Mechanisms of Plaque Rupture in Advanced Atherosclerosis  Ingenuity Systems User Group Meeting Boston MA May 5-6, 2009
What is HRP? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
HRP Initiative Activities ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Plaque Biology Study  CARIM ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
From: Sanz & Fayad, Nature, 451 p 953, 21FEB08 Advanced, Stable Ruptured
 
Sample Collection
The CARIM Sample Set ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Multiple Bioanalytical Analysis Platforms ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Methods of Statistical Analysis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Distribution of Plaque Markers Distinguish Advanced-Stable from Ruptured Plaque 479 235 714 1,190 Px 3,892 3,771 7,663 23,719 Total 3,301 3,499 6,800 22,184 Tx 92 1 93 191 Lipid 20 29 49 118 GC/MS 0 7 7 36 AAA Up in Ruptured Up in Stable Number of markers Number of analytes Platform
IPA Analysis Flowchart ,[object Object],[object Object],[object Object],[object Object]
Top-10 Metabolic Pathways (IPA) Transcripts Proteins Metabolites Significance Ratio
Top-10 Signaling Pathways (IPA) Transcripts Proteins Metabolites Significance Ratio
Canonical Signaling Pathway Analysis: Cellular growth, proliferation and development ,[object Object],[object Object],[object Object],[object Object],[object Object]
Integrin Signaling: Transcripts Only  /   subunit composition Actin cytoskeletal/ focal adhesion downregulation  /   parvin, ILK, PI3K & WNT Signaling
Integrin Signaling: Proteins Only
Integrin Signaling:  -integrin and   -integrin complexes ,[object Object],[object Object],[object Object],Proteins Transcripts
Integrin Signaling: Actin cytoskeletal/focal adhesion downregulation Proteins Transcripts
Integrin Signaling:  /   Parvin, ILK, WNT and PI3K signaling Proteins Transcripts
Canonical Signaling Pathway Analysis : Cellular immune response Highest Tx significance: Role of NFAT in Regulation of the Immune Response (p=3.11E-10)
Role of NFAT in Regulation of Immune Response: Transcripts Only ,[object Object],[object Object]
Role of NFAT in Regulation of Immune Response: Proteins Only ,[object Object],[object Object]
T Helper Cell Differentiation: Transcripts Only
Canonical Signaling Pathway Analysis: Cellular stress and injury ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Coagulation System: Transcripts Only
Coagulation System: Proteins Only
Canonical Signaling Pathway Analysis: Cytokine signaling ,[object Object],[object Object],[object Object],[object Object],Highest Px significance: Acute Phase Responce (p=7.04E-16)
Acute Phase Response Signaling: Transcripts Only
Acute Phase Response Signaling: Proteins Only Likely binding partners are integrins ITGAM & ITGB2 Origin of many of these proteins likely hepatic (outside of plaques)
Canonical Signaling Pathway Analysis: Nuclear receptor signaling ,[object Object],[object Object],[object Object],[object Object]
PPAR  /RXR   Activation : Transcripts Only
PPAR  /RXR   Activation : Proteins Only
Canonical Signaling Pathway Analysis: Organismal growth and development ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Actin Cytoskeleton Signaling: Transcripts Only
Actin Cytoskeleton Signaling: Proteins Only
General Observations on Canonical Pathway Analysis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Summary ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Thank You ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Mais conteúdo relacionado

Mais procurados

Q biomarkersomaticmutation
Q biomarkersomaticmutationQ biomarkersomaticmutation
Q biomarkersomaticmutation
Elsa von Licy
 
Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor...
Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor...Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor...
Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor...
Maté Ongenaert
 
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
Rafael Casiano
 
Whitepaper serumplasma
Whitepaper serumplasmaWhitepaper serumplasma
Whitepaper serumplasma
Elsa von Licy
 
Pcr array whitepaper_app
Pcr array whitepaper_appPcr array whitepaper_app
Pcr array whitepaper_app
Elsa von Licy
 
study of EGFR protein expression and mutation
study of EGFR protein expression and mutation study of EGFR protein expression and mutation
study of EGFR protein expression and mutation
premvarma064
 
Mol Cell Proteomics-2013-Koytiger-1204-13
Mol Cell Proteomics-2013-Koytiger-1204-13Mol Cell Proteomics-2013-Koytiger-1204-13
Mol Cell Proteomics-2013-Koytiger-1204-13
Greg Koytiger
 
Cancer Res-2014-Chakraborty-3489-500
Cancer Res-2014-Chakraborty-3489-500Cancer Res-2014-Chakraborty-3489-500
Cancer Res-2014-Chakraborty-3489-500
Rachel Stupay
 
Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...
Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...
Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...
New York City College of Technology Computer Systems Technology Colloquium
 

Mais procurados (20)

Rare Mutation Analysis Using Digital PCR on QuantStudio™ 3D to Verify Ion Amp...
Rare Mutation Analysis Using Digital PCR on QuantStudio™ 3D to Verify Ion Amp...Rare Mutation Analysis Using Digital PCR on QuantStudio™ 3D to Verify Ion Amp...
Rare Mutation Analysis Using Digital PCR on QuantStudio™ 3D to Verify Ion Amp...
 
TINAGL1 and B3GALNT1 are potential therapy target genes to suppress metastasi...
TINAGL1 and B3GALNT1 are potential therapy target genes to suppress metastasi...TINAGL1 and B3GALNT1 are potential therapy target genes to suppress metastasi...
TINAGL1 and B3GALNT1 are potential therapy target genes to suppress metastasi...
 
Inhibition of the mtorc pathway in the antiphospholipid
Inhibition of the mtorc pathway in the antiphospholipidInhibition of the mtorc pathway in the antiphospholipid
Inhibition of the mtorc pathway in the antiphospholipid
 
Tyrosinekinase inhibitors rahul
Tyrosinekinase inhibitors  rahulTyrosinekinase inhibitors  rahul
Tyrosinekinase inhibitors rahul
 
Q biomarkersomaticmutation
Q biomarkersomaticmutationQ biomarkersomaticmutation
Q biomarkersomaticmutation
 
Anti-cancer as Protein kinase C & tyrosine inhibitor.
Anti-cancer as Protein kinase C & tyrosine inhibitor.Anti-cancer as Protein kinase C & tyrosine inhibitor.
Anti-cancer as Protein kinase C & tyrosine inhibitor.
 
Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor...
Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor...Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor...
Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor...
 
mTOR inhibitor in cancer
mTOR inhibitor in cancermTOR inhibitor in cancer
mTOR inhibitor in cancer
 
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
 
Whitepaper serumplasma
Whitepaper serumplasmaWhitepaper serumplasma
Whitepaper serumplasma
 
From trials evaluating drugs to trials evaluating treatment algorithms – Focu...
From trials evaluating drugs to trials evaluating treatment algorithms – Focu...From trials evaluating drugs to trials evaluating treatment algorithms – Focu...
From trials evaluating drugs to trials evaluating treatment algorithms – Focu...
 
Signaling events triggered by inactivation of the TSC1-2 Complex: Implication...
Signaling events triggered by inactivation of the TSC1-2 Complex: Implication...Signaling events triggered by inactivation of the TSC1-2 Complex: Implication...
Signaling events triggered by inactivation of the TSC1-2 Complex: Implication...
 
Development of a high throughput in vitro screening platform to identify nove...
Development of a high throughput in vitro screening platform to identify nove...Development of a high throughput in vitro screening platform to identify nove...
Development of a high throughput in vitro screening platform to identify nove...
 
Epidermal growth factor(egf)
Epidermal growth factor(egf)Epidermal growth factor(egf)
Epidermal growth factor(egf)
 
Pcr array whitepaper_app
Pcr array whitepaper_appPcr array whitepaper_app
Pcr array whitepaper_app
 
study of EGFR protein expression and mutation
study of EGFR protein expression and mutation study of EGFR protein expression and mutation
study of EGFR protein expression and mutation
 
Receptor Tyrosine Kinase
Receptor Tyrosine KinaseReceptor Tyrosine Kinase
Receptor Tyrosine Kinase
 
Mol Cell Proteomics-2013-Koytiger-1204-13
Mol Cell Proteomics-2013-Koytiger-1204-13Mol Cell Proteomics-2013-Koytiger-1204-13
Mol Cell Proteomics-2013-Koytiger-1204-13
 
Cancer Res-2014-Chakraborty-3489-500
Cancer Res-2014-Chakraborty-3489-500Cancer Res-2014-Chakraborty-3489-500
Cancer Res-2014-Chakraborty-3489-500
 
Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...
Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...
Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...
 

Semelhante a Mechanisms of Plaque Rupture in Advanced Atherosclerosis

Drug metabolism and toxicity 2013
Drug metabolism and toxicity 2013Drug metabolism and toxicity 2013
Drug metabolism and toxicity 2013
Elsa von Licy
 
Biomarker for genotoxicity 2013
Biomarker for genotoxicity 2013Biomarker for genotoxicity 2013
Biomarker for genotoxicity 2013
Elsa von Licy
 
Whole Transcriptome Analysis of Testicular Germ Cell Tumors
Whole Transcriptome Analysis of Testicular Germ Cell TumorsWhole Transcriptome Analysis of Testicular Germ Cell Tumors
Whole Transcriptome Analysis of Testicular Germ Cell Tumors
Thermo Fisher Scientific
 
062011 sanofi seminar
062011 sanofi seminar062011 sanofi seminar
062011 sanofi seminar
milanoj1
 
Pp gef rt2_profiler_0212_web
Pp gef rt2_profiler_0212_webPp gef rt2_profiler_0212_web
Pp gef rt2_profiler_0212_web
Elsa von Licy
 

Semelhante a Mechanisms of Plaque Rupture in Advanced Atherosclerosis (20)

Cell-based Reporter Assays: Measure 45 Signaling Pathway Activity in Any Cell...
Cell-based Reporter Assays: Measure 45 Signaling Pathway Activity in Any Cell...Cell-based Reporter Assays: Measure 45 Signaling Pathway Activity in Any Cell...
Cell-based Reporter Assays: Measure 45 Signaling Pathway Activity in Any Cell...
 
Cell-based Reporter Assays: Measure 45 Signaling Pathway Activity in Any Cel...
 Cell-based Reporter Assays: Measure 45 Signaling Pathway Activity in Any Cel... Cell-based Reporter Assays: Measure 45 Signaling Pathway Activity in Any Cel...
Cell-based Reporter Assays: Measure 45 Signaling Pathway Activity in Any Cel...
 
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug Discovery
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug DiscoveryBioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug Discovery
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug Discovery
 
Drug metabolism and toxicity 2013
Drug metabolism and toxicity 2013Drug metabolism and toxicity 2013
Drug metabolism and toxicity 2013
 
Ttp Lab Tech Talk 051810
Ttp Lab Tech Talk 051810Ttp Lab Tech Talk 051810
Ttp Lab Tech Talk 051810
 
Biomarker for genotoxicity 2013
Biomarker for genotoxicity 2013Biomarker for genotoxicity 2013
Biomarker for genotoxicity 2013
 
Whole Transcriptome Analysis of Testicular Germ Cell Tumors
Whole Transcriptome Analysis of Testicular Germ Cell TumorsWhole Transcriptome Analysis of Testicular Germ Cell Tumors
Whole Transcriptome Analysis of Testicular Germ Cell Tumors
 
Predictive Models for Mechanism of Action Classification from Phenotypic Assa...
Predictive Models for Mechanism of Action Classification from Phenotypic Assa...Predictive Models for Mechanism of Action Classification from Phenotypic Assa...
Predictive Models for Mechanism of Action Classification from Phenotypic Assa...
 
062011 sanofi seminar
062011 sanofi seminar062011 sanofi seminar
062011 sanofi seminar
 
Multiplex Assays for Studying Gene Regulation and Cell Function
Multiplex Assays for Studying Gene Regulation and Cell FunctionMultiplex Assays for Studying Gene Regulation and Cell Function
Multiplex Assays for Studying Gene Regulation and Cell Function
 
Sot2007
Sot2007Sot2007
Sot2007
 
Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2
Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2
Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2
 
Cloning and extracellular expression of recombinant tissue plasminogen activa...
Cloning and extracellular expression of recombinant tissue plasminogen activa...Cloning and extracellular expression of recombinant tissue plasminogen activa...
Cloning and extracellular expression of recombinant tissue plasminogen activa...
 
Cloning and Extracellular Expression of Recombinant Tissue Plasminogen Activa...
Cloning and Extracellular Expression of Recombinant Tissue Plasminogen Activa...Cloning and Extracellular Expression of Recombinant Tissue Plasminogen Activa...
Cloning and Extracellular Expression of Recombinant Tissue Plasminogen Activa...
 
Cloning and extracellular expression of recombinant tissue plasminogen activa...
Cloning and extracellular expression of recombinant tissue plasminogen activa...Cloning and extracellular expression of recombinant tissue plasminogen activa...
Cloning and extracellular expression of recombinant tissue plasminogen activa...
 
CLONING AND EXTRACELLULAR EXPRESSION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVA...
CLONING AND EXTRACELLULAR EXPRESSION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVA...CLONING AND EXTRACELLULAR EXPRESSION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVA...
CLONING AND EXTRACELLULAR EXPRESSION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVA...
 
A next generation sequencing based sample-to-result pharmacogenomics research...
A next generation sequencing based sample-to-result pharmacogenomics research...A next generation sequencing based sample-to-result pharmacogenomics research...
A next generation sequencing based sample-to-result pharmacogenomics research...
 
Pp gef rt2_profiler_0212_web
Pp gef rt2_profiler_0212_webPp gef rt2_profiler_0212_web
Pp gef rt2_profiler_0212_web
 
My PhD Thesis seminar - April 2007
My PhD Thesis seminar - April 2007My PhD Thesis seminar - April 2007
My PhD Thesis seminar - April 2007
 
Epigenetics 2013
Epigenetics 2013Epigenetics 2013
Epigenetics 2013
 

Mais de Tom Plasterer

Enabling Discovery in High-Risk Plaque using Semantic Web Approaches
Enabling Discovery in High-Risk Plaque using Semantic Web ApproachesEnabling Discovery in High-Risk Plaque using Semantic Web Approaches
Enabling Discovery in High-Risk Plaque using Semantic Web Approaches
Tom Plasterer
 

Mais de Tom Plasterer (10)

FAIR Data Knowledge Graphs–from Theory to Practice
FAIR Data Knowledge Graphs–from Theory to PracticeFAIR Data Knowledge Graphs–from Theory to Practice
FAIR Data Knowledge Graphs–from Theory to Practice
 
Making Data FAIR (Findable, Accessible, Interoperable, Reusable)
Making Data FAIR (Findable, Accessible, Interoperable, Reusable)Making Data FAIR (Findable, Accessible, Interoperable, Reusable)
Making Data FAIR (Findable, Accessible, Interoperable, Reusable)
 
FAIR Data Knowledge Graphs
FAIR Data Knowledge GraphsFAIR Data Knowledge Graphs
FAIR Data Knowledge Graphs
 
Dataset Catalogs as a Foundation for FAIR* Data
Dataset Catalogs as a Foundation for FAIR* DataDataset Catalogs as a Foundation for FAIR* Data
Dataset Catalogs as a Foundation for FAIR* Data
 
BioPharma and FAIR Data, a Collaborative Advantage
BioPharma and FAIR Data, a Collaborative AdvantageBioPharma and FAIR Data, a Collaborative Advantage
BioPharma and FAIR Data, a Collaborative Advantage
 
Edge Informatics and FAIR (Findable, Accessible, Interoperable and Reusable) ...
Edge Informatics and FAIR (Findable, Accessible, Interoperable and Reusable) ...Edge Informatics and FAIR (Findable, Accessible, Interoperable and Reusable) ...
Edge Informatics and FAIR (Findable, Accessible, Interoperable and Reusable) ...
 
Harnessing Edge Informatics to Accelerate Collaboration in BioPharma (Bio-IT ...
Harnessing Edge Informatics to Accelerate Collaboration in BioPharma (Bio-IT ...Harnessing Edge Informatics to Accelerate Collaboration in BioPharma (Bio-IT ...
Harnessing Edge Informatics to Accelerate Collaboration in BioPharma (Bio-IT ...
 
Linked Data for Biopharma
Linked Data for BiopharmaLinked Data for Biopharma
Linked Data for Biopharma
 
Enabling Discovery in High-Risk Plaque using Semantic Web Approaches
Enabling Discovery in High-Risk Plaque using Semantic Web ApproachesEnabling Discovery in High-Risk Plaque using Semantic Web Approaches
Enabling Discovery in High-Risk Plaque using Semantic Web Approaches
 
Biomarker Strategies
Biomarker StrategiesBiomarker Strategies
Biomarker Strategies
 

Mechanisms of Plaque Rupture in Advanced Atherosclerosis

Notas do Editor

  1. KEY POINT: Majority of pathway analysis from the pink box; some specific pathway observations checked against cell type analysis
  2. KEY POINT: Sets up integrin story Observations from comparative analysis: Vervain All Modalities
  3. KEY POINT: starting slide for integrin story, sets up slides for the three sub-stories (integrin receptor, cytoskeletal rearrangements, ILK/PI3K/WNT signaling) MD/Maastricht: they have published on the integrins before; good candidates for imaging
  4. KEY POINT: genes/proteins generally agree (down in R/S) Observations from comparative analysis: Vervain All Modalities
  5. KEY POINT: differential use of alpha/beta subunits in ruptured vs. stable plaque indicate differential upstream &amp; downstream signaling Observations from comparative analysis: Vervain All Modalities
  6. KEY POINT: likely loss of cytoskeletal structures in ruptured plaque, loss of internal focal adhesion. Consistent in Px &amp; Tx Observations from comparative analysis: Vervain All Modalities Striking agreement among both proteins and transcripts for actin, alpha-actinin, talin (all complexes) and vinculin. This is suggestive of a weakening of the actin cytoskeleton in ruptured plaques, possibly due to integrin signaling.
  7. KEY POINT: Differential integrin receptor use and secondary messenger use promotes WNT signaling in plaques while demoting PI3K signaling &amp; growth factor signaling. Again both Px &amp; Tx story. WNT signaling, however, is generally downregulated despite contributions from GSK3B. Observations from comparative analysis: Vervain All Modalities
  8. KEY POINT: majority of response in transcripts—many of these are low copy number analytes Observations from comparative analysis: Vervain All Modalities NFAT = Nuclear factor of activated T-cells
  9. Observations from comparative analysis: Vervain All Modalities Many may be lymphocyte specific
  10. Observations from comparative analysis: Vervain All Modalities
  11. KEY POINT: Dominated by transcripts; TNF receptor 11B (Osteoprotegerin) is a possible decoy receptor but downregulation may contribute to calcification. Other TNF receptors (1A, 1B) are pro-apoptic. All three are part of the “TNFR” cluster. MD/Maastricht: t-cells also invade from circulation and proliferate in the adventitia (low numbers relative to other cells would explain lack of Px)
  12. Observations from comparative analysis: Vervain All Modalities
  13. Many proteins here from serum, hence synthesized by liver. MD/Maastricht: also proteins of local/plaque origin!
  14. KEY POINT: proteomics response driven by hepatic origin
  15. Observations from comparative analysis: Vervain All Modalities
  16. Observations from comparative analysis: Vervain All Modalities
  17. KEY POINT: C3 has the integrin a/b partners ITGAM &amp; ITGB2. Proteomics response driven by hepatic origin; cytoplasmic representation of proteins likely out of context; Observations from comparative analysis: Vervain All Modalities
  18. Observations from comparative analysis: Vervain All Modalities
  19. KEY POINT: differential response from the inflammatory (IL-1) route from the TGFb route (SMC migration). Mostly a Tx response due to low copy numbers. Note differential enrichment: IL-1 route (inflammation) up, TGFb route (vascular SMC migration) down! Most obsevation are for transcripts only (low expression levels).
  20. NOT a strong protein response. Many of the transcripts seen are low-intensity transcripts (where is the crossover point?) –OR—they’re not made into proteins—OR—proteomics sample prep isn’t capturing everything that Tx sample prep is.
  21. Observations from comparative analysis: Vervain All Modalities
  22. KEY POINT: actin signaling down in ruptured; also implicated from integrin pathways. Observations from comparative analysis: Vervain All Modalities MD/Maastricht: may be cell specific; not a general abnormality rendering stable more vulnerable
  23. Observations from comparative analysis: Vervain All Modalities Note other than actin and PFN, hardly any of these proteins are components of the cytoskeleton